(MENAFN- IMARC Group)
IMARC Group's report titled“ Hemostasis and Tissue Sealing Agents market Report by Product Type (Topical Hemostats, Adhesive and Tissue Sealant), Material Type (Collagen-based, Oxidized Regenerated Cellulose (ORC) based, Gelatin-based, Polysaccharide-based, and Others), Application (General Surgery, Minimally Invasive Surgery, and Others), End User (Hospitals, Ambulatory Surgical Centers, Home Care Settings, and Others), and Region 2024-2032 “, The global hemostasis and tissue sealing agentsmarket size reached US$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/hemostasis-tissue-sealing-agents-market/requestsample
Factors Affecting the Growth of the Hemostasis and Tissue Sealing Agents Industry:
Technological Advancements in Hemostatic Products:
Innovations in biocompatible and absorbable materials and the development of products that offer enhanced efficacy in bleeding control and wound healing are pushing the boundaries of surgical care. Manufacturers are focusing on creating products that not only provide immediate hemostasis but also support tissue regeneration and reduce the risk of infection. The introduction of combination products that integrate hemostasis and tissue sealing functions offers surgeons more versatile and effective tools, improving patient outcomes. This progress is supported by increasing investments in research and development (R&D) by key market players, aiming to address the diverse needs of surgical procedures. These technological advancements are not only improving the safety and effectiveness of surgeries but also driving the adoption of these agents across a broad range of medical specialties.
Rising Demand for Minimally Invasive Surgeries (MIS):
Minimally invasive surgical techniques, such as laparoscopy, endoscopy, and robotic surgeries, are preferred by surgeons and patients due to their benefits of reduced pain, shorter hospital stays, quicker recovery, and minimal scarring. These advantages are increasing patient preference for minimally invasive surgery (MIS) and catalyzing the demand for hemostasis and tissue sealing agents tailored for these procedures. These agents play a critical role in MIS by ensuring effective bleeding control in a limited operational field and enhancing the visibility of surgeons.
Increasing Focus on Surgical Safety and Efficiency:
Healthcare institutions and surgeons are focusing on reducing operative times, minimizing the risk of surgical complications, and enhancing patient recovery processes. Hemostasis and tissue sealing agents contribute to these goals by providing rapid and reliable control of bleeding, reducing the risk of postoperative hemorrhage, and promoting faster tissue healing. These benefits are particularly valuable in complex surgeries where precision and time are critical. The need for improved surgical outcomes is encouraging continuous innovation in the development of hemostasis and tissue sealing products, making them indispensable in modern surgical practices. This focus on enhancing surgical protocols and patient care standards underscores the essential role of these essential agents.
Leading Companies Operating in the Global Hemostasis and Tissue Sealing Agents Industry:
Advance Medical Solution Group Plc. Artivion Inc., B. Braun Melsungen AG Baxter International Inc. Becton, Dickinson & Company Integra LifeSciences Corporation Johnson & Johnson Medtronic plc Pfizer Inc. Smith & Nephew plc Terumo Corporation
Hemostasis and Tissue Sealing Agents Market Report Segmentation:
By Product Type:
Topical Hemostats Adhesive and Tissue Sealant
Based on the product type, the market has been categorized into collagen-based, oxidized regenerated cellulose (ORC) based, gelatin-based, polysaccharide-based, and others.
By Application:
General Surgery Minimally Invasive Surgery Others
General surgery represents the largest segment, as these procedures often involve complex tissue manipulation and incisions, necessitating effective hemostasis and tissue sealing solutions.
By End User:
Hospitals Ambulatory Surgical Centers Home Care Settings Others
On the basis of the end user, the market has been divided into hospitals, ambulatory surgical centers, home care settings, and others.
Regional Insights:
North America (United States, Canada) Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others) Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others) Latin America (Brazil, Mexico, Others) Middle East and Africa
North America dominates the market owing to the existence of advanced healthcare infrastructure, high adoption rates of innovative surgical technologies, and rising healthcare expenditure.
Global Hemostasis and Tissue Sealing Agents Market Trends:
The growing development of nanoscale materials and bioengineered agents that offer superior hemostatic efficacy, biocompatibility, and tissue adhesion properties compared to conventional products is positively influencing the market. The use of nanotechnology enables the design of agents that can be more precisely targeted to the site of bleeding, providing faster and more effective hemostasis with reduced risk of adverse reactions. Biomaterials, including natural and synthetic polymers, are being engineered to mimic the natural healing processes of the body, enhancing tissue repair and regeneration post-surgery.
Additionally, the increasing interest in personalized medicine is fostering the development of customizable hemostatic and tissue sealing agents that can be tailored to individual patient needs based on specific surgical requirements or underlying health conditions.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email:
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
MENAFN22022024004122016232ID1107884132
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.